Celularity
CELUPhase 2Celularity is a leader in regenerative and cellular medicine, harnessing the unique biology of the postpartum placenta to create a scalable pipeline of allogeneic cell therapies and biomaterial products. With a deep scientific foundation spanning over two decades, the company has transitioned from its origins as Anthrogenesis (founded 1998) to a publicly traded entity with a robust clinical pipeline and commercial capabilities. Its strategy focuses on overcoming traditional barriers in cell therapy—scale, quality, and economics—to deliver effective, off-the-shelf treatments for serious conditions, supported by a seasoned leadership team and integrated manufacturing infrastructure.
CELU · Stock Price
Historical price data
AI Company Overview
Celularity is a leader in regenerative and cellular medicine, harnessing the unique biology of the postpartum placenta to create a scalable pipeline of allogeneic cell therapies and biomaterial products. With a deep scientific foundation spanning over two decades, the company has transitioned from its origins as Anthrogenesis (founded 1998) to a publicly traded entity with a robust clinical pipeline and commercial capabilities. Its strategy focuses on overcoming traditional barriers in cell therapy—scale, quality, and economics—to deliver effective, off-the-shelf treatments for serious conditions, supported by a seasoned leadership team and integrated manufacturing infrastructure.
Technology Platform
Proprietary platform utilizing postpartum placenta to derive allogeneic, cryopreserved cell therapies (MLASCs, NK Cells, T Cells) and advanced biomaterials, designed for scalable, off-the-shelf production.
Pipeline Snapshot
1717 drugs in pipeline
| Drug | Indication | Stage |
|---|---|---|
| 3 x 10^6 cells + 10 x 10^6 cells + 30 x 10^6 cells | Peripheral Arterial Disease | Phase 2 |
| Human Placenta-Derived Cells PDA001 Intravenous Infusion + Vehice Control | Crohn's Disease | Phase 2 |
| PDA001 + Vehicle Controlled Placebo | Rheumatoid Arthritis | Phase 2 |
| PDA-002 + Placebo | Diabetic Nephropathies | Phase 2 |
| PDA-002 + Placebo | Diabetic Foot | Phase 2 |
Opportunities
Risk Factors
Competitive Landscape
Competes with allogeneic cell therapy developers (e.g., Fate Therapeutics, Allogene), MSC companies (e.g., Mesoblast), and advanced wound care firms (e.g., Organogenesis). Differentiation is based on its proprietary placental cell source, which offers unique biological properties, and its integrated, large-scale manufacturing capabilities designed for cost-effective production.
Company Info
Trading
Contact
Therapeutic Areas
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile